SLSBio(Specialty Lab Solution Bio) Co., Ltd

에스엘에스바이오246250KOSDAQSector: Others

₩1,9690.00%Market cap ₩30.2BAs of Sep 3, 2026 close · updated once daily

Market cap

₩30.2B

#1398 in KOSDAQ

Loss

PER not computable

3.96x

Sector median 0.79x

0.0%

Sector median 0.6%

Trading halted — grade display suspended

This stock is under a trading halt per KRX disclosure. Grade display resumes once trading resumes.

See withholding criteria →View source filing (DART) ↗

This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1-year closing price

Low ₩1,969High ₩1,969

Latest close

Price change by period

0.00%

As of the Sep 3, 2026 close · updated once daily · a factual record computed from closing prices only; dividends are not included, and this is not a buy or sell signal.

Financial strength

38.5/100

How much debt does it carry relative to equity?

47.1%

Sector median 80.3%

Sector low

highTop 29.3% in sector

Can it cover what's due within a year?

285.0%

Sector median 144.8%

Sector low

highTop 21.1% in sector

How much of revenue becomes profit?

-103.0%

Sector median 4.8%

Sector low

highBottom 1.1% in sector

How much did it earn on its own capital?

-64.2%

Sector median 5.2%

Sector low

highBottom 3.3% in sector

Source filing: annual report (separate) — view original ↗

Growth momentum

2.5/100

How much did revenue grow in a year?

-52.4%

Sector median 3.2%

Sector low

highBottom 1.2% in sector

Has it grown steadily over three years?

-28.2%

Sector median 0.9%

Sector low

highBottom 3.3% in sector

Did core profits grow in a year?

-1527.4%

Sector median 12.1%

Sector low

highBottom 1.2% in sector

Are core profits higher than three years ago?

-269.4%

Sector median -0.4%

Sector low

highBottom 4.2% in sector

Financial trend

Revenue

Growth & margin

Revenue growth Operating margin

Year over year — alongside the sector median

This stock Sector median

A factual chart of confirmed annual results from annual reports — the same source as the grading indicators. Not a buy or sell signal.

Source filing: annual report (separate) — view original ↗

Price attractiveness

8.9/100

Is the price expensive relative to earnings?

Loss-making (P/E not computable)

Sector median P/E of profitable peers 11.1x · 26% loss-making

Sector low

highBottom 12.2% in sector

Is the price expensive relative to book value?

3.96x

Sector median 0.79x

Sector low

highBottom 5.6% in sector

Valuation uses the Sep 3, 2026 close and market cap

Shareholder Return

Single-indicator axis24.1/100

Does the company actually pay dividends?

0.0%

Sector median 0.6%

Sector low

highBottom 24.1% in sector

Dividends & treasury shares

Treasury shares (FY2025): 300,151 shares (1.9% of shares issued)

Source: annual report (DART) — dividend allocation & total shares

Source filing: annual report (separate) — view original ↗

Financial checklist

Based on the FY2025 annual report · year-over-year comparison · determined on Sep 2, 2026

Of 9 items: 2 met · 7 not met · 0 not computable

Not metMetNot computable

Positive net income

Whether net income (attributable to owners where available) is above zero.

Not met

-₩4.9B

Positive operating cash flow

Whether cash flow from operations is above zero.

Not met

-₩2.2B

Return on assets up

Whether net income over beginning total assets rose from the prior year.

Not met

1.9% → -30.0%

Operating cash flow exceeds net income

Whether operating cash flow is greater than net income.

Met

-₩2.2B vs -₩4.9B

Liabilities-to-assets ratio down

Whether total liabilities as a share of total assets fell from the prior year.

Not met

23.5% → 32.0%

Current ratio up

Whether current assets over current liabilities rose from the prior year.

Not met

663.9% → 285.0%

Shares outstanding not increased

Whether common shares issued did not increase from the prior year. Increases from bonus issues and stock dividends are also counted.

Met

15,348,206 → 15,348,206

Operating margin up

Whether operating income over revenue rose from the prior year.

Not met

3.4% → -103.0%

Asset turnover up

Whether revenue over beginning total assets rose from the prior year.

Not met

0.47x → 0.24x

A record of facts determined by fixed rules from the financial statements in the latest annual report. Not used in grading, and not a buy or sell signal. Source filing: annual report (separate) — view original ↗

Grade change history

Jul 23, 2026F

Methodology version change (v2.0 applied)

Jul 15, 2026FVersion v1

First calculation

Grade changes are a factual record produced from public data by a fixed formula; they do not signal future changes.

Disclosure & financial badges

Factual records determined from public filings and periodic reports by fixed rules — not buy/sell signals.

Negative-evidence group (dilution, loss, dispute)Mixed interpretationPositive-evidence group (shareholder return)Dots classify the disclosure type by the direction of research evidence — not an assessment or investment judgment about this company.

Disclosure event history

Corporate value-up plan filed

Filed a “기업가치제고계획(자율공시)” (corporate value-up plan, voluntary disclosure) (filed 2025-05-30). View filing ↗

Determined as of 2026-09-02

Recent filings for this stock

Last 120 days · monitored filing types only

Periodic report filedAug 14, 2026Source ↗

Periodic report filedMay 15, 2026Source ↗

View in the filings calendar →